NCT06393114

Impacts of Fermented Plant-based Products High in Protein on Gut Microbiota and Health

Name: Clinical Trial NCT06393114
Creator: University of Eastern Finland
Keywords: Metabolic Syndrome, Fermented oat-based product, other, clinical trial, Finland

Impacts of Fermented Plant-based Products High in Protein and Fibre on Gut Microbiota and Health: a Randomized, Controlled, Cross-over Trial

University of Eastern Finland·ClinicalTrials.gov·otherRecruitment Completed

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Metabolic Syndrome
Drug/Device/Intervention: Fermented oat-based product
Study type: Interventional
Intervention type: other

Sponsor & location

Primary sponsor: University of Eastern Finland
Location: Kuopio, Finland

Timeline & enrollment

Phase: N/A
Start date: Jan 22, 2024
End date: Dec 01, 2024
Enrollment: 100 participants

Primary outcome

Inflammatory marker 1,Inflammatory marker 2,Inflammatory marker 3

Summary

This study aims to investigate the effects of consuming fermented oat-based products on gut and overall human health. It is a randomized, controlled, cross-over trial with a dietary intervention.  A total of 100 participants will be enrolled in this study and they will eat both fermented and unfermented oat-based products for three weeks. Participants will eat their habitual diet between the dietary intervention periods (wash-out).  During the study, participants' perceived health, inflammatory markers, glucose and lipid metabolism, tryptophan metabolites, gastrointestinal symptoms, and gut microbiota will be assessed.

ICD-10 classifications

Metabolic disordersMetabolic disorder, unspecifiedOther metabolic disordersOther specified metabolic disordersNutritional and metabolic disorders in diseases classified elsewhere

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06393114
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06393114 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Eastern Finland and is currently Recruitment Completed. The study focuses on Metabolic Syndrome. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.